Europe – EU approves Tukysa combo for advanced HER2-positive breast cancer

Seagen International (Seagen) has announced that the European Commission (EC) has approved a marketing authorisation for its HER2 tyrosine kinase inhibitor (TKI) Tukysa for the treatment of HER2-positive locally-advanced or metastatic breast cancer.

The EC has approved the use of Tukysa (tucatinib) in combination with trastuzumab and capecitabine for the treatment of adult patients with advanced HER2-positive breast cancer, who have received at least two prior anti-HER2 treatments.

In Seagen’s HER2CLIMB trial of Tukysa, patients who received the TKI in combination with trastuzumab and capecitabine had a 46% reduction in the risk of cancer progression or death – progression-free survival (PFS)…